Biomaterials for Cardiac Tissue Engineering

Arnal-Pastor, M.; Chachques, Juan Carlos; Pradas, Manuel Monleón; Lluch, Ana Valles

doi:10.5772/56076

Cited by 12 publications

(12 citation statements)

References 222 publications

(263 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such strategies fail to retain large amount of administered cells within the target tissue and maintain their long-term cell viability, since post-infarcted tissue exhibits localized hypoxia, nutrient depletion, inflammatory and oxidative stress, apoptotic cytokines, and fibrotic tissue deposition (Russo et al, 2014). Alternate platforms such as patches or injectables are being explored for cellular delivery, localization, and engraftment to the target site, which could also provide an appropriate 3D niche by supplying biological, pharmaceutical, and mechanical signals to the pathological tissue and aid in tissue regeneration and reversal of adverse ventricular remodeling processes (Arnal-Pastor, Chachques, Pradas, & Vallés-Lluch, 2013;Joshi & Kothapalli, 2015;Lakshmanan, Krishnan, & Sethuraman, 2012).…”

Section: Introductionmentioning

confidence: 99%

Three‐dimensional collagenous niche and azacytidine selectively promote time‐dependent cardiomyogenesis from human bone marrow‐derived MSC spheroids

Joshi

Mahajan

Kothapalli

2018

Biotech & Bioengineering

View full text Add to dashboard Cite

Endogenous adult cardiac regenerative machinery is not capable of replacing the lost cells following myocardial infarction, often leading to permanent alterations in structure-function-mechanical properties. Regenerative therapies based on delivering autologous stem cells within an appropriate 3D milieu could meet such demand, by enabling homing and directed differentiation of the transplanted cells into lost specialized cell populations. Since type I collagen is the predominant cardiac tissue matrix protein, we here optimized the 3D niche which could promote time-dependent evolution of cardiomyogenesis from human bone marrow-derived mesenchymal stem cells (BM-MSC). 3D collagen gel physical and mechanical characteristics were assessed using SEM and AFM, respectively, while the standalone and combined effects of collagen concentration, culture duration, and 5-azacytidine (aza) dose on the phenotype and genotype of MSC spheroids were quantified using immunofluorescence labeling and RT-PCR analysis. Increasing collagen concentration led to a significant increase in Young's modulus (p < 0.01) but simultaneous decrease in the mean pore size, resulting in stiffer gels. Spheroid formation significantly modulated MSC differentiation and genotype, mostly due to better cell-cell interactions. Among the aza dosages tested, 10 μM appears to be optimal, while 3 mg/ml gels resulted in significantly lower cell viability compared to 1 or 2 mg/ml gels. Stiffer gels (2 and 3 mg/ml) and exposure to 10 μM aza upregulated early and late cardiac marker expressions in a time-dependent fashion. On the other hand, cell-cell signaling within the MSC spheroids seem to have a strong role in influencing mature cardiac markers expression, since neither aza nor gel stiffness seem to significantly improve their expression. Western blot analysis suggested that canonical Wnt/β-catenin signaling pathway might be primarily mediating the observed benefits of aza on cardiac differentiation of MSC spheroids. In conclusion, 2 mg/ml collagen and 10 μM aza appears to offer optimal 3D microenvironment in terms of cell viability and time-dependent evolution of cardiomyogenesis from human BM-MSCs, with significant applications in cardiac tissue engineering and stem cell transplantation for regenerating lost cardiac tissue.

show abstract

Section: Introductionmentioning

confidence: 99%

Three‐dimensional collagenous niche and azacytidine selectively promote time‐dependent cardiomyogenesis from human bone marrow‐derived MSC spheroids

Joshi

Mahajan

Kothapalli

2018

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…Therefore, new therapies are currently being explored. In particular, cell-based therapies have become a new focal point for the treatment of various CVDs, aiming to restore function and structure of damaged heart by implantation of cells into the pathologic tissue using a variety of techniques (e.g., intracoronary, intravenous, intramyocardial, and trans-endocardial injection methods) [13].…”

Section: Scaffold-free Cellular Approachesmentioning

confidence: 99%

Engineering Functional Cardiac Tissues for Regenerative Medicine Applications

et al. 2019

View full text Add to dashboard Cite

Purpose of Review Tissue engineering has expanded into a highly versatile manufacturing landscape that holds great promise for advancing cardiovascular regenerative medicine. In this review, we provide a summary of the current state-of-the-art bioengineering technologies used to create functional cardiac tissues for a variety of applications in vitro and in vivo. Recent Findings Studies over the past few years have made a strong case that tissue engineering is one of the major driving forces behind the accelerating fields of patient-specific regenerative medicine, precision medicine, compound screening, and disease modeling. To date, a variety of approaches have been used to bioengineer functional cardiac constructs, including biomaterialbased, cell-based, and hybrid (using cells and biomaterials) approaches. While some major progress has been made using cellular approaches, with multiple ongoing clinical trials, cell-free cardiac tissue engineering approaches have also accomplished multiple breakthroughs, although drawbacks remain. Summary This review summarizes the most promising methods that have been employed to generate cardiovascular tissue constructs for basic science or clinical applications. Further, we outline the strengths and challenges that are inherent to this field as a whole and for each highlighted technology.

show abstract

“…(C) : Various cardiac patch strategies and epicardial patch placement. (B, C) : Reproduced from [93] with permission. Abbreviations: AV, aortic valve, MV, mitral valve, PV, pulmonary valve, TV, tricuspid valve.…”

Section: Implantation Locationmentioning

confidence: 99%